Results 231 to 240 of about 1,444,670 (278)

Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis [PDF]

Cell Reports, 2022
Immune checkpoint inhibitors (ICIs) are an effective therapy for various cancers; however, they can induce immune-related adverse events (irAEs) as a side effect. Myocarditis is an uncommon, but fatal, irAE caused after ICI treatments.
Taejoon Won, Ninaad Lasrado, Mónica V Talor   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management

Annals of Pharmacotherapy, 2023
Objective: To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). Data Sources: A literature search was conducted on PubMed from origin to
Alyssa Sykuta, Connie H. Yoon, Sarah Baldwin, Natalie I. Rine, Michael Young, Adam Smith   +5 more
openaire   +2 more sources

Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy

Cardiology in Review, 2023
Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel, Andy, Wang, Srihari S, Naidu, William H, Frishman, Wilbert S, Aronow   +4 more
openaire   +2 more sources

Cardiac Myosin Inhibitors: Unlocking Potential to Improve Treatment in Hypertrophic Cardiomyopathy

Circulation, 2023
Andrew Wang
exaly   +3 more sources

Target population for a selective cardiac myosin inhibitor in hypertrophic obstructive cardiomyopathy: Real-life estimation from the French register of hypertrophic cardiomyopathy (REMY)

Archives of Cardiovascular Diseases
Background: The efficacy of current pharmacological therapies in hypertrophic cardiomyopathy is limited. A cardiac myosin inhibitor, mavacamten, has recently been approved as a first-in-class treatment for symptomatic hypertrophic obstructive ...
Alessandro Parodi, Tania Puscas Muresan
exaly   +3 more sources

Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

Annals of Pharmacotherapy, 2022
Objective: To assess mavacamten’s role in hypertrophic cardiomyopathy treatment. Data Sources: In addition to clinical guidelines, package inserts, and general reviews, we searched PubMed using the term mavacamten from inception to ...
Joseph D. Dalo, Nissen D. Weisman, C. Michael White   +2 more
openaire   +2 more sources

Cardiac Myosin Inhibitors

Journal of the American College of Cardiology
Morten S Jensen, Torsten B Rasmussen, Anne Mette Dybro   +2 more
exaly   +2 more sources

Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy

Current Opinion in Cardiology, 2023
Purpose of review Cardiac myosin inhibitors (CMIs) represent a major milestone in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The objective of this review is to discuss the mechanisms of action, clinical trial evidence, safety profile and monitoring of CMIs, which are important to the ...
Safia, Chatur, Sheila M, Hegde
openaire   +2 more sources